Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

The injection process is expected to take ... s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

The cash injection comes as Biogen has been hit hard by the stalled rollout of its Alzheimer's disease drug Aduhelm (aducanumab), with Stat reporting earlier this month that the company is ...

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080 ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Biogen has agreed to buy UK-based gene therapy ... NSR-REP1 is comprised of an AAV vector administered by subretinal injection which provides a functioning CHM gene and expression of the REP ...

February 28, 2025 EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug The European Union's medicines regulator on Friday reiterated its positive recommendation for ...